Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet in Hyperparathyroid Dialysis Patients
NCT04637360Completed
- Sponsor
- Min-Sheng General Hospital
- Start
- Jan 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Min-Sheng General Hospital. Primary endpoint: Parathyroid hormone at 6 months. Started Jan 2018; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT04637360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637360.